Biotree is a technology company.
Biotree has raised $13.0M across 1 funding round.
Biotree has raised $13.0M in total across 1 funding round.
Biotree has raised $13.0M in total across 1 funding round.
Biotree's investors include Qiming Venture Partners.
Biotree is a Shanghai-based technology company specializing in metabolomics solutions for the life sciences and healthcare industries. Founded in 2013, it offers a broad range of services including non-targeted and targeted metabolomics, lipidomics, proteomics, and related software and hardware for data analysis. Its clients include academic institutions, research labs, hospitals, and pharmaceutical companies. Biotree addresses the critical need for advanced biochemical analysis to support research, diagnostics, and drug development, positioning itself as a key player in the metabolomics field with ongoing growth supported by $14.8 million in funding from investors like Qiming Venture Partners and KingMed Diagnostics[1][4][5].
Biotree was established in 2013 in Shanghai, China, with a focus on applying innovative mass spectrometry technologies to life sciences and medical health. The company quickly expanded its capabilities by introducing advanced platforms such as GC-TOF-MS and q-exactive Orbitrap high-resolution LC-MS. Strategic partnerships with academic institutions like the Chinese Academy of Sciences and collaborations with international firms such as Umetrics (Sweden) helped Biotree build credibility and technical depth. Key milestones include obtaining ISO certifications, medical device registrations, and recognition as a national high-tech enterprise. Leadership includes experts like Dr. He Jingquan, appointed president of Baiqu Health Research Institute, underscoring the company’s scientific expertise[4].
Biotree operates at the intersection of biotechnology and data science, riding the global trend toward precision medicine and systems biology. The increasing demand for metabolomics data to understand disease mechanisms, drug responses, and personalized health solutions creates a favorable market environment. Advances in mass spectrometry and bioinformatics, combined with growing healthcare investments in Asia, position Biotree to influence the metabolomics ecosystem significantly. By enabling high-quality biochemical data generation and analysis, Biotree supports innovation in drug discovery, diagnostics, and life science research, contributing to the broader shift toward data-driven healthcare[1][4].
Looking ahead, Biotree is poised to expand its technological capabilities and market footprint, leveraging its strong scientific foundation and strategic partnerships. Trends such as personalized medicine, multi-omics integration, and AI-driven data analysis will likely shape its product development and service offerings. Continued investment in regulatory compliance and international collaborations could accelerate its global presence. As metabolomics becomes more central to healthcare innovation, Biotree’s role as a provider of comprehensive, high-quality metabolomics solutions will likely grow, reinforcing its influence in the life sciences technology landscape[1][4][5].
Biotree has raised $13.0M across 1 funding round. Most recently, it raised $13.0M Series A in July 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2022 | $13.0M Series A | Qiming Venture Partners |